Drugs / aCD19z cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01493453 | Mar 2008 → Dec 2014 | B-cell non-Hodgkin lymphoma | The Christie NHS Foundation Trust | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aCD19z cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01493453 ↗ |
| Modality | Cell therapy | “Genetically modified T cells engineered to express chimeric immune receptors (CIRs) on their cell surface” NCT01493453 ↗ |
| Route | Intravenous | “aCD19z T cells IV Day 1” NCT01493453 ↗ |
| Target | CD19 | “using T cells expressing a CD19 targeting CIR by retroviral transduction of the CIR into activated T cells in order to target B cell malignancies” NCT01493453 ↗ |